Core AD biomarkers were significantly higher (T-tau, P-tau181) or lower (Aβ42) in AD compared to every other group (p < 0.0001 for all three) and in SCD compared to controls (Aβ42, p = 0.011; T-tau, p = 0.039; P-tau181, p = 0.002) (Fig. 2b–d). The gene discussed is MAPT; the disease is Alzheimer disease.